Daniel Castellano
@cdanicas
Followers
4K
Following
12K
Media
486
Statuses
8K
Medical Oncologist. Hospital Univ. 12 de Octubre. Madrid. UCM. Head GU Unit. Executive Member @GUARDconsortitum
Joined January 2013
RT @urotoday: SASAN-SPARING trial: Bladder-sparing approach for muscle-invasive #BladderCancer. @elenasefer joins @zklaassen_md @GACancerCe….
0
6
0
RT @ASCO: Explore open funding opportunities through @ConquerCancerFd Grants & Awards program. There’s funding for researchers at every car….
0
3
0
RT @DrYukselUrun: In aRCC patients treated with nivolumab, high baseline IL-6, IL-8, and VEGF = worse outcomes. IL-6 & IL-8 linked to myelo….
0
8
0
RT @AndreaNecchi: Exploratory biomarker analyses of adjuvant #nivolumab in urothelial carcinoma from #CheckMate274 trial are out in @Nature….
0
32
0
RT @CACancerJournal: PARP inhibitors comprise a therapeutic class that targets PARP proteins involved in DNA repair. This #OpenAccess revie….
0
39
0
RT @DrYukselUrun: A mind-opener review on muscle-invasive bladder cancer. Must-read for GU oncologist. #BladderCancer #Oncology #Immunother….
0
60
0
RT @DrYukselUrun: New in #HeadAndNeckCancer research: The HANCOCK dataset , 763 patients, multi‑modal real‑world data (demographics, pathol….
0
9
0
RT @OncoAlert: Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS . . Thi….
0
8
0
RT @APCCC_Lugano: Nivolumab and Ipilimumab for Metastatic Castration-Resistant #ProstateCancer With an Immunogenic Signature: The Multicent….
0
24
0
RT @drenriquegrande: ⚡️ @JCO_ASCO - The management of Muscle Invasive Bladder Cancer is entering a new era. Integration of immune checkpoin….
0
25
0
RT @AndreaNecchi: Urinary Tumor DNA–based Liquid Biopsy in Bladder Cancer Management: A Systematic Review - European Urology Focus https://….
eu-focus.europeanurology.com
Urinary tumor DNA has emerged as a promising biomarker in bladder cancer care, enhancing diagnosis, early detection, staging, treatment planning, recurrence monitoring, and prognosis due to its...
0
12
0
RT @TelixPharma: Illuccix® (kit for the preparation of 68Ga-PSMA-11 injection*) is now listed on the Medicare Benefits Schedule in Australi….
0
4
0
RT @g_develasco: 🚨 When EV/pembro is not an option, what's the best first-line strategy for cisplatin-ineligible patients with advanced uro….
ascopubs.org
PURPOSEImmune checkpoint inhibitors combined with platinum-based chemotherapy is standard in patients with advanced/metastatic urothelial carcinoma (mUC). Cisplatin has immunomodulatory benefits...
0
17
0
RT @ASCOPres: I'm pleased to launch a new series, "Science Matters." We’ll explore why science matters, and which scientific 'matters' are….
connection.asco.org
2025-2026 ASCO president Dr. Eric Small introduces “Science Matters,” a series of interviews and videos which will discuss how scientific discovery drives real-world change.
0
35
0
🎯 Seguimos avanzando en mejorar el diagnóstico precoz y tratamiento de los pacientes con cáncer urotelial!!🙌.@DanaeUrogenomics nuestra startup de biop. líquida y #medicinaprecisión @DrFelixGuerrero @FaltasLab @ChristianRolfo @ASEICAnews @Ecastromarcos @DBarreiro4.
El sistema #BlaDimir detecta pequeñas moléculas en la orina producidas por células tumorales. Una técnica sencilla para detectar el #cáncer de vejiga. Investigadores del #Hospital12DeOctubre y el #Ciemat crean una startup para impulsarlo. Vía @RTVEMadrid . @SaludMadrid .#ciencia
1
6
21
RT @APCCC_Lugano: PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patie….
0
10
0
RT @DrMHofman: A new PET biomarker in men with high-risk metastatic castration-resistant prostate cancer. Total tumor volume prognostic for….
0
30
0
RT @DrFelixGuerrero: Investigadores del Hospital público 12 de Octubre crean una startup para mejorar el diagnóstico y realizar medicina de….
0
7
0